Phenotypically occult multidrug-resistant Mycobacterium tuberculosis: Dilemmas in diagnosis and treatment

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 12, 2013, Pages 2915-2920

  Ho, Jennifer ^a,b   Jelfs, Peter ^a   Sintchencko, Vitali ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

High dose rifampicin; Low level resistance; Rifampicin; Rpob mutation; Treatment failure

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT;

ADULT; ARTICLE; BACTERIUM ISOLATION; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR TYPING; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; RELAPSE; TREATMENT FAILURE; TREATMENT OUTCOME;

HIGH-DOSE RIFAMPICIN; LOW-LEVEL RESISTANCE; RIFAMPICIN; RPOB MUTATION; TREATMENT FAILURE;

ADULT; ANTITUBERCULAR AGENTS; DNA, BACTERIAL; DNA-DIRECTED RNA POLYMERASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84887519076     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt284     Document Type: Article

References (35)

1. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009; 13: 1320-30.
2. Williamson DA, Roberts SA, Bower JE et al. Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2012; 16: 216-20.
3. Wayne LG. Simple pyrazinamidase and urease tests for routine identification ofmycobacteria. Am Rev Respir Dis 1974; 109: 147-51.
4. Ahmad S, Mokaddas E. The occurrence of rare rpoB mutations in rifampicin-resistant clinical Mycobacterium tuberculosis isolates from Kuwait. Int J Antimicrob Agents 2005; 26: 205-12.
5. Palomino JC, Traore H, Fissette K et al. Evaluation ofMycobacteria Growth Indicator Tube (MGIT) for drug susceptibility testing of Mycobacterium tuberculosis. Int J Tuberc Lung Dis 1999; 3: 344-8.
6. Giampaglia CMS, Martins MC, Chimara E et al. Differentiation of Mycobacterium tuberculosis from other mycobacteria with r-nitrobenzoic acid using MGIT960. Int J Tuberc Lung Dis 2007; 11: 803-7.
7. Boehme CC, Nabeta P, Hillemann D et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363: 1005-15.
8. Hillemann D, Rusch-Gerdes S, Richter E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2007; 45: 2635-40.
9. Supply P, Allix C, Lesjean S et al. Proposal for standardization of optimized mycobacterial interspersed repetitiveunit-variable-numbertandemrepeat typing of Mycobacterium tuberculosis. J Clin Microbiol 2006; 44: 4498-510.
10. Dickinson JM, Mitchison DA. Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Am Rev Respir Dis 1981; 123: 367-71.
11. Jindani A, Dore CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 2003; 167: 1348-54.
12. Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 2000; 4: 796-806.
13. Zaczek A, Brzostek A, Augustynowicz-Kopec E et al. Genetic evaluation of relationship betweenmutations in rpoB and resistance of Mycobacterium tuberculosis to rifampin. BMC Microbiol 2009; 9: 10.
14. Williams DL, Spring L, Collins L et al. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998; 42: 1853-7.
15. Bodmer T, Zürcher G, Imboden P et al. Mutation position and type of substitution in the b subunit of the RNA polymerase influence in vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis. J Antimicrob Chemother 1995; 35: 345-8.
16. van Ingen J, Aarnoutse R, de Vries G et al. Low-level rifampicin-resistant Mycobacterium tuberculosis strains raise a newtherapeutic challenge. Int J Tuberc Lung Dis 2011; 15: 990-2.
17. VanDeunA, BarreraL, Bastian I et al. Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. J Clin Microbiol 2009; 47: 3501-6.
18. Gumbo T. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrob Agents Chemother 2010; 54: 1484-91.
19. Gumbo T, Louie A, Deziel MR et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007; 51: 3781-8.
20. Goutelle S, Bourguignon L, Maire PH et al. Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob Agents Chemother 2009; 53: 2974-81.
21. Diacon AH, Patientia RF, Venter A et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother 2007; 51: 2994-6.
22. Verbist L, Gyselen A. Antituberculous activity of rifampin in vitro and in vivo and the concentrations attained in human blood. Am Rev Respir Dis 1968; 98: 923-32.
23. Dickinson JM, Mitchison DA. Suitability of rifampicin for intermittent administration in the treatment of tuberculosis. Tubercle 1970; 51: 82-94.
24. Verbist L. Rifampicin activity 'in vitro' and in established tuberculosis in mice. Acta tuberculosea et pneumologica Belgica 1969; 60: 397-412.
25. Steingart KR, Jotblad S, Robsky K et al. Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis 2011; 15: 305-16.
26. Mitnick CD, McGee B, Peloquin CA. Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin Pharmacother 2009; 10: 381-401.
27. Poole G, Stradling P, Worlledge S. Potentially serious side-effects of high-dose twice-weekly rifampicin. Postgrad Med J 1971; 47: 727-47.
28. Aquinas M, Allan WG, Horsfall PA et al. Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong. Br Med J 1972; 1: 765-71.
29. Bertrand A. Antibiotic treatment of brucellosis. Presse Med 1994; 23: 1128-31.
30. Drancourt M, Stein A, Argenson JN et al. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother 1997; 39: 235-40.
31. Kochar DK, Aseri S, Sharma BV et al. The role of rifampicin in the management of cutaneous leishmaniasis. QJM 2000; 93: 733-7.
32. Ruslami R, Nijland H, Aarnoutse R et al. Evaluation of high- versus standard-dose rifampin in Indonesian patients with pulmonary tuberculosis. Antimicrob Agents Chemother 2006; 50: 822-3.
33. Barry C, Waring J, Stapledon R et al. Tuberculosis notifications in Australia, 2008 and 2009. Commun Dis Intell 2012; 36: 82-94.
34. WHO. Treatment of Tuberculosis Guidelines, 4th Edition. 2010. http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf (7 June 2013, date last accessed).
35. WHO. Global Tuberculosis Report 2012. http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf (7 June 2013, date last accessed